Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASP5502
- Development stage
- Discontinued
- Lead developer
- Astellas Pharma Global Development, Inc.
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ASP5502 is an investigational small molecule drug developed by Astellas Pharma for the treatment of primary Sjögren's syndrome. It is a first-in-human, orally administered compound currently in Phase 1 clinical trials. The drug was designed using artificial intelligence to target immune homeostasis, with its mechanism of action believed to involve inhibition of STING (Stimulator of Interferon Genes), a key regulator in innate immunity and inflammation. The primary indication under investigation is primary Sjögren's syndrome, an autoimmune disease characterized by dry mouth and eyes due to lymphocytic infiltration of exocrine glands.
- Other names
- ASP-5502ASP5502ASP 5502
02
Targets
STING (Stimulator of interferon genes protein)
Beyond the preview
Go deeper on ASP5502.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASP5502.